XJPX
4925
Market cap40mUSD
Oct 09, Last price
1,680.00JPY
1D
-0.47%
1Q
-3.45%
Jan 2017
-56.81%
IPO
-58.00%
Name
Haba Laboratories Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Established in Tokyo, Japan, in 1983, HABA Laboratories, Inc. develops and distributes a comprehensive range of skincare, hair, and body care items both domestically and across international markets. Their skincare portfolio encompasses facial cleansers, toners, specialized treatments, and squalane oils, while their hair and body offerings include shampoos, conditioners, soaps, and various hair and hand care solutions. Consumers can acquire these products through multiple avenues, such as mail order, their online platform, various retail outlets including drug and variety stores, and at around 70 dedicated HABA shops located in major department stores and shopping complexes.
Key people
Noriko Koyanagi
Chairman of the Board · since 2025
Tomotaka Matsui
Director · since 2021
Mikio Nishi
Director · since 2024
Yoshinori Nishimura
Director · since 2020
Akihiko Takasaki
Director · since 2023
Yamaoka Teruaki
Director · since 2023
Taira Kashino
Independent Director · since 2025
Nobuko Kato
Independent Director · since 2023
Fumie Ueda
Independent Director · since 2025
Tsunekazu Umeda
Independent Director · since 2015
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑03 | 2025‑03 | 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||